Make Informed Investment Decisions with Affordable Access to Experts
A discussion on the Ulcerative Colitis Landscape - Where does PN-10943 fit in against Tofacitinib, Ozanimod, Etrolizumab, and Entyvio?Ticker(s): PTGX, PFE, RHHBY, CELG, TKPYY
Name: Dr Francis Farraye - MD | MSc
Institution: Boston University
- Clinical Director, Section of Gastroenterology, Director, Inflammatory Bowel Disease Center at Boston Medical Center and Professor of Medicine at BU School of Medicine.
- Currently treats 60-70 ulcerative colitis patients per month.
- Special Interests in Ulcerative colitis, Crohn's disease, Inflammatory Bowel Disease
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.